This work was supported by the Cr(VI) Panel of the ACC. ACC had no role in study design, data collection and analysis, decision to publish or preparation of any manuscript. The funders were given the opportunity to review the draft study design as it went through an external peer review process and draft manuscripts at the time of external peer review. The purpose of such review was to allow input on the clarity of the science presented but not in interpretation of the research findings. The researchers’ scientific conclusions and professional judgments were not subject to the funders’ control; the contents of this manuscript reflect solely the view of the authors.
A chronic oral reference dose for hexavalent chromium-induced intestinal cancer†
Version of Record online: 14 AUG 2013
© 2013 The Authors. Journal of Applied Toxicology published by John Wiley & Sons, Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Applied Toxicology
Volume 34, Issue 5, pages 525–536, May 2014
How to Cite
Thompson, C. M., Kirman, C. R., Proctor, D. M., Haws, L. C., Suh, M., Hays, S. M., Hixon, J. G. and Harris, M. A. (2014), A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J. Appl. Toxicol., 34: 525–536. doi: 10.1002/jat.2907
- Issue online: 26 MAR 2014
- Version of Record online: 14 AUG 2013
- Manuscript Accepted: 2 JUN 2013
- Manuscript Revised: 15 MAY 2013
- Manuscript Received: 19 OCT 2012
- risk assessment;
- hexavalent chromium Cr(VI);
- mode of action;
- benchmark dose (BMD) modeling;
- constrained nonlinear regression;
- cancer reference dose (RfD);
- intestinal cancer
High concentrations of hexavalent chromium [Cr(VI)] in drinking water induce villous cytotoxicity and compensatory crypt hyperplasia in the small intestines of mice (but not rats). Lifetime exposure to such cytotoxic concentrations increases intestinal neoplasms in mice, suggesting that the mode of action for Cr(VI)-induced intestinal tumors involves chronic wounding and compensatory cell proliferation of the intestine. Therefore, we developed a chronic oral reference dose (RfD) designed to be protective of intestinal damage and thus intestinal cancer. A physiologically based pharmacokinetic model for chromium in mice was used to estimate the amount of Cr(VI) entering each intestinal tissue section (duodenum, jejunum and ileum) from the lumen per day (normalized to intestinal tissue weight). These internal dose metrics, together with corresponding incidences for diffuse hyperplasia, were used to derive points of departure using benchmark dose modeling and constrained nonlinear regression. Both modeling techniques resulted in similar points of departure, which were subsequently converted to human equivalent doses using a human physiologically based pharmacokinetic model. Applying appropriate uncertainty factors, an RfD of 0.006 mg kg–1 day–1 was derived for diffuse hyperplasia—an effect that precedes tumor formation. This RfD is protective of both noncancer and cancer effects in the small intestine and corresponds to a safe drinking water equivalent level of 210 µg l–1. This concentration is higher than the current federal maximum contaminant level for total Cr (100 µg l–1) and well above levels of Cr(VI) in US drinking water supplies (typically ≤ 5 µg l–1). © 2013 The Authors. Journal of Applied Toxicology published by John Wiley & Sons, Ltd.